Novartis Announced Tafinlar (Dabrafenib) + Mekinist (Trametinib) Significantly Improved Efficacy In Patients Ages 1 To 17 Years Old With Braf V600 Paediatric Low-Grade Glioma (Plgg) Requiring First Systemic Treatment Compared To Chemotherapy, The Current Standard-Of-Care For These Patients. In This Study, Patients Randomized To Receive Tafinlar + Mekinist Experienced A Statistically Significant Overall Response Rate (Orr) Of 47% (Ci: 35-59%) Compared To 11% (Ci: 3-25%, P<0.001) For Those Randomized To Receive Chemotherapy. A New Liquid Formulation Of Tafinlar + Mekinist That Can Be Easier To Administer Than Chemotherapy Was Used In This Trial. The Data Highlighted As Part Of An Official Press Briefing And Oral Presentation At The 2022 American Society Of Clinical Oncology (Asco) Annual Meeting (Abstract #Lba2002).
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!